A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Nrf2 over-expression in mesenchymal stem cells to improve cellular cardiomyoplasty
[dataset]
2014
Figshare
Myocardial infarction (MI) is the leading cause of death worldwide. Various therapeutic strategies have been introduced for MI treatment. In recent years, interest in utilizing mesenchymal stem cells (MSCs) for MI therapy has increased. In fact, the use of MSCs for MI treatment, known as cellular cardiomyoplasty, is in the clinical trial stage. However, despite promising results, most MSCs die after transplantation as a result of exposure to various stresses. Nuclear factor (erythroid-derived
doi:10.6084/m9.figshare.1035784.v2
fatcat:4zoxfmc7yzdpfmg5zt5xdfyw2m